Information on the target
Altaris has successfully completed the acquisition of the Life Sciences & Healthcare (LS&H) business from Clarivate, marking a significant milestone in the healthcare sector. This business specializes in providing AI-enabled data intelligence and decision-support tools tailored for research and development (R&D) and commercialization within the pharmaceutical, biotechnology, and medical technology industries. With a workforce of approximately 2,300 employees spread across 22 countries, LS&H is well-positioned to leverage its extensive expertise and resources in the healthcare landscape.
Under the leadership of CEO Henry Levy, who will continue to guide the newly independent company, LS&H aims to enhance its service offerings and expand its market reach. The acquisition allows Altaris to capitalize on the growing demand for data-driven solutions in life sciences, particularly as the industry increasingly relies on advanced analytics to drive innovation and efficiency.
Industry overview in the target’s specific country
The Pharmaceuticals (NEC) industry in the United States is characterized by rapid innovation and a strong emphasis on research and development. The U.S. remains a global leader in pharmaceutical advancements, driven by significant investments in biotechnology and a robust regulatory framework that supports the introduction of new therapies. The industry is marked by a diverse range of companies, from large multinational corporations to specialized biotech firms, all contributing to a dynamic market landscape.
In recent years, the U.S. pharmaceutical sector has seen a surge in the adoption of artificial intelligence and machine learning technologies. These advancements are transforming drug discovery processes, enabling companies to analyze vast datasets more efficiently and identify potential therapeutic candidates with greater accuracy. As a result, the integration of AI into R&D is not only enhancing productivity but also accelerating the time-to-market for new drugs.
Moreover, the ongoing shift towards personalized medicine is reshaping the industry, with a growing focus on developing targeted therapies that cater to individual patient needs. This trend is supported by an increasing amount of genomic and clinical data, which pharmaceutical companies are leveraging to create more effective treatments. The U.S. market is also witnessing a rise in collaborations between pharmaceutical firms and technology companies, further driving innovation and expanding the capabilities of the industry.
As the demand for innovative healthcare solutions continues to grow, the Pharmaceuticals (NEC) industry in the U.S. is poised for sustained growth. The combination of a strong regulator…